Blink Dx is at the forefront of advanced molecular diagnostics, focusing on innovative solutions to combat antibiotic resistance and improve health outcomes. Their flagship platform, the BLINK One, enables rapid detection of pathogens and their antimicrobial resistance genes directly from samples. This technology is designed to be cost-effective and efficient, catering to both human and animal health needs. By leveraging cutting-edge multiplexing techniques, Blink Dx aims to provide timely and accurate diagnostic results, which are crucial in addressing the growing challenge of antibiotic resistance.

In collaboration with Rutgers University, Blink Dx is also developing a revolutionary tuberculosis (TB) diagnostic tool that integrates drug resistance assays with their proprietary nanoreactor bead technology. This sample-to-answer molecular diagnostic test is specifically tailored for resource-limited settings, allowing for quick and precise identification of TB and its drug-resistant mutations. Through these innovative approaches, Blink Dx is not only enhancing diagnostic capabilities but also contributing significantly to public health initiatives aimed at controlling infectious diseases.

Germany

Home of the BLINK Beads, the BLINK X and the BLINK One. 

BLINK is revolutionizing the field of bioanalytics and diagnostics. We have created next-generation microfluidics-free digital PCR technology that combines sample nucleic acid extraction, multiplex analysis and quantification in a single compact workflow.

Our rapid, ultra-sensitive digital multiplex assays empower scientists and clinicians to make high-impact discoveries and enables rapid molecular diagnostics to achieve an immediate, targeted therapy, ultimately leading to better patient outcomes and a more effective healthcare system. 

Blink Dx

Company Details